Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neurocrine Biosciences Inc NBIX

Healthcare Biotechnology
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington... see more

Recent & Breaking News (NDAQ:NBIX)

Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders

Business Wire June 16, 2020

Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference

PR Newswire June 15, 2020

Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020

PR Newswire June 8, 2020

Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast

PR Newswire June 4, 2020

FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women

PR Newswire May 29, 2020

Neurocrine Biosciences to Present at the Jefferies Virtual Healthcare Conference

PR Newswire May 26, 2020

Neurocrine Biosciences to Present at the RBC Capital Markets 2020 Global Healthcare Conference

PR Newswire May 14, 2020

Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform

PR Newswire May 13, 2020

Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy

PR Newswire May 11, 2020

Neurocrine Biosciences Announces New Data Published from the Largest Real-World Screening Study, RE-KINECT, Demonstrating that Movements Consistent with Tardive Dyskinesia Occur Frequently and Can Reduce Quality of Life in Patients with Psychiatric Disorders

PR Newswire May 7, 2020

Neurocrine Biosciences Reports First Quarter 2020 Financial Results

PR Newswire May 6, 2020

Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2020

PR Newswire May 5, 2020

Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes

PR Newswire April 27, 2020

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2020 Financial Results

PR Newswire April 15, 2020

Neurocrine Biosciences Provides COVID-19 Business Update

PR Newswire April 3, 2020

Neurocrine Biosciences to Present at Cowen 40th Annual Health Care Conference

PR Newswire February 25, 2020

Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results

PR Newswire February 4, 2020

Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors

PR Newswire February 3, 2020

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results

PR Newswire January 20, 2020

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

GlobeNewswire January 13, 2020